132 related articles for article (PubMed ID: 23347435)
1. A comparison between intensive and conventional cabergoline treatment of newly diagnosed patients with macroprolactinoma.
Rastogi A; Bhansali A; Dutta P; Singh P; Vijaivergiya R; Gupta V; Sachdeva N; Bhadada SK; Walia R
Clin Endocrinol (Oxf); 2013 Sep; 79(3):409-15. PubMed ID: 23347435
[TBL] [Abstract][Full Text] [Related]
2. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients.
Colao A; Di Sarno A; Landi ML; Scavuzzo F; Cappabianca P; Pivonello R; Volpe R; Di Salle F; Cirillo S; Annunziato L; Lombardi G
J Clin Endocrinol Metab; 2000 Jun; 85(6):2247-52. PubMed ID: 10852458
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of cabergoline on rapid escalation of dose in men with macroprolactinomas.
Bhansali A; Walia R; Dutta P; Khandelwal N; Sialy R; Bhadada S
Indian J Med Res; 2010 Apr; 131():530-5. PubMed ID: 20424304
[TBL] [Abstract][Full Text] [Related]
4. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients.
Ono M; Miki N; Kawamata T; Makino R; Amano K; Seki T; Kubo O; Hori T; Takano K
J Clin Endocrinol Metab; 2008 Dec; 93(12):4721-7. PubMed ID: 18812485
[TBL] [Abstract][Full Text] [Related]
5. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.
Colao A; Di Sarno A; Landi ML; Cirillo S; Sarnacchiaro F; Facciolli G; Pivonello R; Cataldi M; Merola B; Annunziato L; Lombardi G
J Clin Endocrinol Metab; 1997 Nov; 82(11):3574-9. PubMed ID: 9360509
[TBL] [Abstract][Full Text] [Related]
6. Treatment of macroprolactinoma with cabergoline: a study of 85 patients.
Ferrari CI; Abs R; Bevan JS; Brabant G; Ciccarelli E; Motta T; Mucci M; Muratori M; Musatti L; Verbessem G; Scanlon MF
Clin Endocrinol (Oxf); 1997 Apr; 46(4):409-13. PubMed ID: 9196602
[TBL] [Abstract][Full Text] [Related]
7. Evaluaton of therapy with cabergoline in men with macroprolactinoa.
Andrysiak-Mamos E; Kaźmierczyk-Puchalska A; Zochowska E; Sowińska-Przepiera E; Sagan L; Kojder I; Syrenicz A
Pomeranian J Life Sci; 2015; 61(3):263-9. PubMed ID: 27344867
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of short-term maintenance treatment with cabergoline in microadenoma-related and idiopathic hyperprolactinemia.
Buyukbayrak EE; Karageyim Karsidag AY; Kars B; Balcik O; Pirimoglu M; Unal O; Turan C
Arch Gynecol Obstet; 2010 Nov; 282(5):561-6. PubMed ID: 20571820
[TBL] [Abstract][Full Text] [Related]
9. Secondary deterioration of visual field during cabergoline treatment for macroprolactinoma.
Raverot G; Jacob M; Jouanneau E; Delemer B; Vighetto A; Pugeat M; Borson-Chazot F
Clin Endocrinol (Oxf); 2009 Apr; 70(4):588-92. PubMed ID: 18673461
[TBL] [Abstract][Full Text] [Related]
10. Giant prolactinomas in men: efficacy of cabergoline treatment.
Corsello SM; Ubertini G; Altomare M; Lovicu RM; Migneco MG; Rota CA; Colosimo C
Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
[TBL] [Abstract][Full Text] [Related]
11. Cabergoline treatment in a case of macroprolactinoma after delivery.
Falsetti L
Acta Eur Fertil; 1995; 26(3):105-7. PubMed ID: 9098469
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of rapid escalation of cabergoline in comparison to conventional regimen for macroprolactinoma: A prospective, randomized trial.
Rastogi A; Walia R; Dutta P; Bhansali A
Indian J Endocrinol Metab; 2012 Dec; 16(Suppl 2):S294-6. PubMed ID: 23565404
[TBL] [Abstract][Full Text] [Related]
13. Tumour shrinkage and chiasmal herniation after successful cabergoline treatment for a macroprolactinoma.
Marcos L; De Luis DA; Botella I; Hurtado A
Clin Endocrinol (Oxf); 2001 Jan; 54(1):126-7. PubMed ID: 11167937
[No Abstract] [Full Text] [Related]
14. Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma.
Cannavò S; Curtò L; Squadrito S; Almoto B; Vieni A; Trimarchi F
J Endocrinol Invest; 1999 May; 22(5):354-9. PubMed ID: 10401709
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of cabergoline in the treatment of macroprolactinoma].
Dupuy O; Le Marec E; Mayaudon H; Rilminger H; Bordier L; Bauduceau B
Presse Med; 2003 Jan; 32(2):71-2. PubMed ID: 12653031
[No Abstract] [Full Text] [Related]
16. Secondary resistance to cabergoline therapy in a macroprolactinoma: a case report and literature review.
Behan LA; Draman MS; Moran C; King T; Crowley RK; O'Sullivan EP; Smith D; Thompson CJ; Agha A
Pituitary; 2011 Dec; 14(4):362-6. PubMed ID: 19191028
[TBL] [Abstract][Full Text] [Related]
17. Predictors of Chronic LH-Testosterone Axis Suppression in Male Macroprolactinomas With Normoprolactinemia on Cabergoline.
Sehemby M; Lila AR; Sarathi V; Shah R; Sankhe S; Jaiswal SK; Ramteke-Jadhav S; Patil V; Shah N; Bandgar T
J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32942295
[TBL] [Abstract][Full Text] [Related]
18. The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males.
De Rosa M; Ciccarelli A; Zarrilli S; Guerra E; Gaccione M; Di Sarno A; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2006 Mar; 64(3):307-13. PubMed ID: 16487441
[TBL] [Abstract][Full Text] [Related]
19. Serial 3 T magnetic resonance imaging during cabergoline treatment of macroprolactinomas.
Kurosaki M; Kambe A; Watanabe T; Fujii S; Ogawa T
Neurol Res; 2015 Apr; 37(4):341-6. PubMed ID: 25376133
[TBL] [Abstract][Full Text] [Related]
20. Reduction in the size of prolactin-producing pituitary tumor after Cabergoline administration.
Melis GB; Gambacciani M; Paoletti AM; Mais V; Sghedoni D; Fioretti P
Fertil Steril; 1989 Sep; 52(3):412-5. PubMed ID: 2570719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]